5 news items
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
13 May 24
what science can do for patients. Sutro's fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient
What's Going On With Sutro Biopharma (STRO) Stock?
STRO
2 Apr 24
with its existing resources, for various purposes including research, clinical and process development, manufacturing, working capital
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
STRO
2 Apr 24
for general corporate purposes, which may include funding research, clinical and process development and manufacturing of its product candidates
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
STRO
2 Apr 24
science can do for patients. Sutro's fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
25 Mar 24
-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient
- Prev
- 1
- Next